GRAIL/$GRAL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About GRAIL

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Ticker

$GRAL
Sector
Primary listing

Employees

1,000

GRAIL Metrics

BasicAdvanced
$2.2B
-
-$13.06
-
-

What the Analysts think about GRAIL

Analyst ratings (Buy, Hold, Sell) for GRAIL stock.

Bulls say / Bears say

The PATHFINDER 2 study from GRAIL showed higher cancer detection rates than the initial trial, with improvements in positive predictive value, 99.5% specificity, and 88% accuracy in identifying the cancer’s origin, solidifying the test’s clinical credibility (Investing.com).
GRAIL had $677.9 million in cash at the end of the first quarter of 2025, providing enough funding through 2028 to support further commercial expansion and ongoing study submissions for FDA approval (PR Newswire).
Canaccord Genuity keeps a Buy rating on GRAIL, citing its head start in multi-cancer early detection and projecting that achieving regulatory and reimbursement milestones could lift annual test volumes to two million and annual revenue to $800 million by 2032 (Barron’s).
GRAIL posted a net loss of $114.0 million in the second quarter of 2025, with adjusted EBITDA at $(78.3) million, highlighting ongoing unprofitability despite revenue growth (PR Newswire).
The Galleri test does not yet have FDA Premarket Approval and is not widely covered by insurance, limiting its uptake until these regulatory and reimbursement hurdles are overcome (Barron’s).
Rising competition from Guardant Health’s Shield test and Exact Sciences’ Cancerguard test poses a threat to Galleri’s share of the large and profitable multi-cancer screening market (Barron’s).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

GRAIL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GRAIL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GRAL

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs
Buy GRAIL stock | $GRAL Share Price | Lightyear